COVID-19 Project Team: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 66: Line 66:
*[[User:Muhammad Haider|Muhammad Adnan Haider]]
*[[User:Muhammad Haider|Muhammad Adnan Haider]]
*[[User:Agnesrinky|Rinky Agnes Botleroo, M.B.B.S.]]
*[[User:Agnesrinky|Rinky Agnes Botleroo, M.B.B.S.]]
*[[User:Parul Pahal|Parul Pahal, M.B.B.S.]]
'''Ongoing Clinical Trials of COVID-19 Team Members'''
'''Ongoing Clinical Trials of COVID-19 Team Members'''



Revision as of 16:45, 17 June 2020

COVID-19 Project
Introduction
Team
Meetings' Summary
Topics
Ongoing Clinical Trials

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sahar Memar Montazerin, M.D.[2]

Meet The Team

Associate Editor(s)-in-Chief:

  • The name of the leaders are written in bold:

Cardiovascular Disorders of COVID-19 Team Members

Dermatologic Disorders of COVID-19 Team Members

Frequently Asked Inpatient Questions Team Members

Frequently Asked Outpatient Questions Team Members

Gastrointestinal disorders and of COVID-19

Hematologic disorders of COVID-19 Team Members

Nephrologic Disorders of COVID-19 Team Members

Neurologic Disorders and COVID-19 Team Members

Ongoing Clinical Trials of COVID-19 Team Members


Pediatrics and COVID-19

Pulmonary Disorders and COVID-19 Team Members